Maravai LifeSciences' third quarter 2026 revenue of $45.9M beat estimates as mRNA sales surged 28%

Maravai LifeSciences reported third quarter 2026 revenue of $45.9 million, exceeding analyst estimates of $43.56 million. The company narrowed its adjusted net loss to $0.03 per share, significantly outperforming the expected $0.07 loss. Results were driven by a recovery in mRNA demand and continued growth in the Cygnus biologics safety testing business.

Key Highlights

• Total revenue increased 10.1% year-over-year to $45.9 million, supported by a 28% surge in mRNA product sales.
• Adjusted EBITDA turned positive at $5.8 million, representing a significant reversal from the $10.8 million loss reported in the prior year period.
• Management raised full-year 2026 revenue guidance to a range of $212.0 million to $216.0 million and increased the Adjusted EBITDA midpoint by 20%.
• The TriLink segment saw four discovery-stage mRNA customers transition to clinical-stage GMP, bolstering the long-term pipeline for high-value consumables.